Given that EZH2 is considered a major tumor marker and an effective therapeutic target for OC, herein, we evaluated the impact of two EZH2 inhibitors (GSK343 and EPZ6438) on CTO proliferation and polyploidization. Here, EZH2 is linked to neoplasm.